This is a second revised version of a story originally published July 8.

By Alex Philippidis

Pfizer's decision to scuttle its plan to lease 105,000 square feet at the Mission Bay campus in San Francisco — less than a year after agreeing to the deal — is a setback for Mission Bay and the Bay Area's lab-space market, which has slumped with the economy over the past year, but not a crippling blow to either, two real estate professionals agreed this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.